Asian consensus statement of experts on thermal ablation for secondary hyperparathyroidism in chronic kidney disease
- PMID: 40391972
- DOI: 10.1097/JS9.0000000000002510
Asian consensus statement of experts on thermal ablation for secondary hyperparathyroidism in chronic kidney disease
Abstract
Secondary hyperparathyroidism (SHPT) is characterized by parathyroid hyperplasia, persistently elevated parathyroid hormone levels, and disturbances in mineral metabolism. Currently, a considerable amount of literature has consistently shown that thermal ablation is effective in maintaining parathyroid hormone levels within an appropriate range, normalizing calcium and phosphorus levels, improving clinical symptoms, and reducing the volume of parathyroid glands. However, there are currently no established guidelines regarding its utilization. The Asian consensus statement of experts on thermal ablation for SHPT in chronic kidney disease was jointly initiated by experts from China and Korea in the fields of nephrology, interventional ultrasound or radiology, thyroid surgery, ultrasound medicine, nuclear medicine, and diagnostic radiology-to formulate recommendations aimed at establishing standardized protocols for thermal ablation targeting the parathyroid glands. Based on the systematic review of literatures related to ultrasound-guided thermal ablation of parathyroid glands and the professional opinions of experts, the consensus statement covers the relevant content regarding thermal ablation treatment for SHPT, including indications, contraindications, pre-ablation evaluation, operational procedures, post-ablation follow-up, therapeutic effect evaluation, complications prevention and treatment. According to the Grading of Recommendations Assessment, Development and Evaluation, a total of 18 recommendations were given. This consensus statement will positively promote the standardization of ultrasound-guided thermal ablation of parathyroid glands.
Keywords: interventional ultrasound; parathyroid; secondary hyperparathyroidism; thermal ablation.
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.
References
-
- Portillo MR, Rodríguez-Ortiz ME. Secondary hyperparthyroidism: pathogenesis, diagnosis, preventive and therapeutic strategies. Rev Endocr Metab Disord 2017;18:79–95.
-
- Mao J, You H, Wang M, et al. Single-cell RNA sequencing reveals transdifferentiation of parathyroid chief cells into oxyphil cells in patients with uremic secondary hyperparathyroidism. Kidney Int 2024;105:562–81.
-
- Levy AR, Xing S, Brunelli SM, et al. Symptoms of secondary hyperparathyroidism in patients receiving maintenance hemodialysis: a prospective cohort study. Am J Kidney Dis 2020;75:373–83.
-
- Isakova T, Nickolas TL, Denburg M, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2017;70:737–51.
-
- Bozic M, Diaz-Tocados JM, Bermudez-Lopez M, et al. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dialysis Trans 2022;37:663–72.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
